Global Neuroblastoma Treatment Drugs Market Growth 2024-2031

Report ID: 1853796 | Published Date: Jan 2025 | No. of Page: 93 | Base Year: 2024 | Rating: 4.3 | Webstory: Check our Web story
1 Scope of the Report
    1.1 Market Introduction
    1.2 Years Considered
    1.3 Research Objectives
    1.4 Market Research Methodology
    1.5 Research Process and Data Source
    1.6 Economic Indicators
    1.7 Currency Considered
2 Executive Summary
    2.1 World Market Overview
        2.1.1 Global Neuroblastoma Treatment Drugs Annual Sales 2017-2028
        2.1.2 World Current & Future Analysis for Neuroblastoma Treatment Drugs by Geographic Region, 2017, 2022 & 2028
        2.1.3 World Current & Future Analysis for Neuroblastoma Treatment Drugs by Country/Region, 2017, 2022 & 2028
    2.2 Neuroblastoma Treatment Drugs Segment by Type
        2.2.1 Cyclophosphamide
        2.2.2 Dinutuximab
        2.2.3 Naxitamab
        2.2.4 Doxorubicin Hydrochloride
        2.2.5 Vincristine Sulfate
        2.2.6 Other
    2.3 Neuroblastoma Treatment Drugs Sales by Type
        2.3.1 Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)
        2.3.2 Global Neuroblastoma Treatment Drugs Revenue and Market Share by Type (2017-2022)
        2.3.3 Global Neuroblastoma Treatment Drugs Sale Price by Type (2017-2022)
    2.4 Neuroblastoma Treatment Drugs Segment by Application
        2.4.1 Hospital
        2.4.2 Clinic
        2.4.3 Other
    2.5 Neuroblastoma Treatment Drugs Sales by Application
        2.5.1 Global Neuroblastoma Treatment Drugs Sale Market Share by Application (2017-2022)
        2.5.2 Global Neuroblastoma Treatment Drugs Revenue and Market Share by Application (2017-2022)
        2.5.3 Global Neuroblastoma Treatment Drugs Sale Price by Application (2017-2022)
3 Global Neuroblastoma Treatment Drugs by Company
    3.1 Global Neuroblastoma Treatment Drugs Breakdown Data by Company
        3.1.1 Global Neuroblastoma Treatment Drugs Annual Sales by Company (2020-2022)
        3.1.2 Global Neuroblastoma Treatment Drugs Sales Market Share by Company (2020-2022)
    3.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Company (2020-2022)
        3.2.1 Global Neuroblastoma Treatment Drugs Revenue by Company (2020-2022)
        3.2.2 Global Neuroblastoma Treatment Drugs Revenue Market Share by Company (2020-2022)
    3.3 Global Neuroblastoma Treatment Drugs Sale Price by Company
    3.4 Key Manufacturers Neuroblastoma Treatment Drugs Producing Area Distribution, Sales Area, Product Type
        3.4.1 Key Manufacturers Neuroblastoma Treatment Drugs Product Location Distribution
        3.4.2 Players Neuroblastoma Treatment Drugs Products Offered
    3.5 Market Concentration Rate Analysis
        3.5.1 Competition Landscape Analysis
        3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
    3.6 New Products and Potential Entrants
    3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Neuroblastoma Treatment Drugs by Geographic Region
    4.1 World Historic Neuroblastoma Treatment Drugs Market Size by Geographic Region (2017-2022)
        4.1.1 Global Neuroblastoma Treatment Drugs Annual Sales by Geographic Region (2017-2022)
        4.1.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Geographic Region
    4.2 World Historic Neuroblastoma Treatment Drugs Market Size by Country/Region (2017-2022)
        4.2.1 Global Neuroblastoma Treatment Drugs Annual Sales by Country/Region (2017-2022)
        4.2.2 Global Neuroblastoma Treatment Drugs Annual Revenue by Country/Region
    4.3 Americas Neuroblastoma Treatment Drugs Sales Growth
    4.4 APAC Neuroblastoma Treatment Drugs Sales Growth
    4.5 Europe Neuroblastoma Treatment Drugs Sales Growth
    4.6 Middle East & Africa Neuroblastoma Treatment Drugs Sales Growth
5 Americas
    5.1 Americas Neuroblastoma Treatment Drugs Sales by Country
        5.1.1 Americas Neuroblastoma Treatment Drugs Sales by Country (2017-2022)
        5.1.2 Americas Neuroblastoma Treatment Drugs Revenue by Country (2017-2022)
    5.2 Americas Neuroblastoma Treatment Drugs Sales by Type
    5.3 Americas Neuroblastoma Treatment Drugs Sales by Application
    5.4 United States
    5.5 Canada
    5.6 Mexico
    5.7 Brazil
6 APAC
    6.1 APAC Neuroblastoma Treatment Drugs Sales by Region
        6.1.1 APAC Neuroblastoma Treatment Drugs Sales by Region (2017-2022)
        6.1.2 APAC Neuroblastoma Treatment Drugs Revenue by Region (2017-2022)
    6.2 APAC Neuroblastoma Treatment Drugs Sales by Type
    6.3 APAC Neuroblastoma Treatment Drugs Sales by Application
    6.4 China
    6.5 Japan
    6.6 South Korea
    6.7 Southeast Asia
    6.8 India
    6.9 Australia
    6.10 China Taiwan
7 Europe
    7.1 Europe Neuroblastoma Treatment Drugs by Country
        7.1.1 Europe Neuroblastoma Treatment Drugs Sales by Country (2017-2022)
        7.1.2 Europe Neuroblastoma Treatment Drugs Revenue by Country (2017-2022)
    7.2 Europe Neuroblastoma Treatment Drugs Sales by Type
    7.3 Europe Neuroblastoma Treatment Drugs Sales by Application
    7.4 Germany
    7.5 France
    7.6 UK
    7.7 Italy
    7.8 Russia
8 Middle East & Africa
    8.1 Middle East & Africa Neuroblastoma Treatment Drugs by Country
        8.1.1 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Country (2017-2022)
        8.1.2 Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Country (2017-2022)
    8.2 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type
    8.3 Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application
    8.4 Egypt
    8.5 South Africa
    8.6 Israel
    8.7 Turkey
    8.8 GCC Countries
9 Market Drivers, Challenges and Trends
    9.1 Market Drivers & Growth Opportunities
    9.2 Market Challenges & Risks
    9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
    10.1 Raw Material and Suppliers
    10.2 Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs
    10.3 Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
    10.4 Industry Chain Structure of Neuroblastoma Treatment Drugs
11 Marketing, Distributors and Customer
    11.1 Sales Channel
        11.1.1 Direct Channels
        11.1.2 Indirect Channels
    11.2 Neuroblastoma Treatment Drugs Distributors
    11.3 Neuroblastoma Treatment Drugs Customer
12 World Forecast Review for Neuroblastoma Treatment Drugs by Geographic Region
    12.1 Global Neuroblastoma Treatment Drugs Market Size Forecast by Region
        12.1.1 Global Neuroblastoma Treatment Drugs Forecast by Region (2023-2028)
        12.1.2 Global Neuroblastoma Treatment Drugs Annual Revenue Forecast by Region (2023-2028)
    12.2 Americas Forecast by Country
    12.3 APAC Forecast by Region
    12.4 Europe Forecast by Country
    12.5 Middle East & Africa Forecast by Country
    12.6 Global Neuroblastoma Treatment Drugs Forecast by Type
    12.7 Global Neuroblastoma Treatment Drugs Forecast by Application
13 Key Players Analysis
    13.1 United Therapeutics
        13.1.1 United Therapeutics Company Information
        13.1.2 United Therapeutics Neuroblastoma Treatment Drugs Product Offered
        13.1.3 United Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.1.4 United Therapeutics Main Business Overview
        13.1.5 United Therapeutics Latest Developments
    13.2 Y-mAbs Therapeutics
        13.2.1 Y-mAbs Therapeutics Company Information
        13.2.2 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Offered
        13.2.3 Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.2.4 Y-mAbs Therapeutics Main Business Overview
        13.2.5 Y-mAbs Therapeutics Latest Developments
    13.3 EUSA Pharma
        13.3.1 EUSA Pharma Company Information
        13.3.2 EUSA Pharma Neuroblastoma Treatment Drugs Product Offered
        13.3.3 EUSA Pharma Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.3.4 EUSA Pharma Main Business Overview
        13.3.5 EUSA Pharma Latest Developments
    13.4 ANI Pharmaceuticals
        13.4.1 ANI Pharmaceuticals Company Information
        13.4.2 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
        13.4.3 ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.4.4 ANI Pharmaceuticals Main Business Overview
        13.4.5 ANI Pharmaceuticals Latest Developments
    13.5 Baxter Healthcare
        13.5.1 Baxter Healthcare Company Information
        13.5.2 Baxter Healthcare Neuroblastoma Treatment Drugs Product Offered
        13.5.3 Baxter Healthcare Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.5.4 Baxter Healthcare Main Business Overview
        13.5.5 Baxter Healthcare Latest Developments
    13.6 Ingenus Pharmaceuticals
        13.6.1 Ingenus Pharmaceuticals Company Information
        13.6.2 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
        13.6.3 Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.6.4 Ingenus Pharmaceuticals Main Business Overview
        13.6.5 Ingenus Pharmaceuticals Latest Developments
    13.7 Pfizer
        13.7.1 Pfizer Company Information
        13.7.2 Pfizer Neuroblastoma Treatment Drugs Product Offered
        13.7.3 Pfizer Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.7.4 Pfizer Main Business Overview
        13.7.5 Pfizer Latest Developments
    13.8 Hikma Pharmaceuticals
        13.8.1 Hikma Pharmaceuticals Company Information
        13.8.2 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
        13.8.3 Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.8.4 Hikma Pharmaceuticals Main Business Overview
        13.8.5 Hikma Pharmaceuticals Latest Developments
    13.9 Teva Pharmaceuticals
        13.9.1 Teva Pharmaceuticals Company Information
        13.9.2 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
        13.9.3 Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales, Revenue, Price and Gross Margin (2020-2022)
        13.9.4 Teva Pharmaceuticals Main Business Overview
        13.9.5 Teva Pharmaceuticals Latest Developments
14 Research Findings and Conclusion
List of Tables
    Table 1. Neuroblastoma Treatment Drugs Annual Sales CAGR by Geographic Region (2017, 2022 & 2028) & ($ millions)
    Table 2. Neuroblastoma Treatment Drugs Annual Sales CAGR by Country/Region (2017, 2022 & 2028) & ($ millions)
    Table 3. Major Players of Cyclophosphamide
    Table 4. Major Players of Dinutuximab
    Table 5. Major Players of Naxitamab
    Table 6. Major Players of Doxorubicin Hydrochloride
    Table 7. Major Players of Vincristine Sulfate
    Table 8. Major Players of Other
    Table 9. Global Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
    Table 10. Global Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)
    Table 11. Global Neuroblastoma Treatment Drugs Revenue by Type (2017-2022) & ($ million)
    Table 12. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2017-2022)
    Table 13. Global Neuroblastoma Treatment Drugs Sale Price by Type (2017-2022) & (US$/Unit)
    Table 14. Global Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
    Table 15. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)
    Table 16. Global Neuroblastoma Treatment Drugs Revenue by Application (2017-2022)
    Table 17. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application (2017-2022)
    Table 18. Global Neuroblastoma Treatment Drugs Sale Price by Application (2017-2022) & (US$/Unit)
    Table 19. Global Neuroblastoma Treatment Drugs Sales by Company (2020-2022) & (K Units)
    Table 20. Global Neuroblastoma Treatment Drugs Sales Market Share by Company (2020-2022)
    Table 21. Global Neuroblastoma Treatment Drugs Revenue by Company (2020-2022) ($ Millions)
    Table 22. Global Neuroblastoma Treatment Drugs Revenue Market Share by Company (2020-2022)
    Table 23. Global Neuroblastoma Treatment Drugs Sale Price by Company (2020-2022) & (US$/Unit)
    Table 24. Key Manufacturers Neuroblastoma Treatment Drugs Producing Area Distribution and Sales Area
    Table 25. Players Neuroblastoma Treatment Drugs Products Offered
    Table 26. Neuroblastoma Treatment Drugs Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
    Table 27. New Products and Potential Entrants
    Table 28. Mergers & Acquisitions, Expansion
    Table 29. Global Neuroblastoma Treatment Drugs Sales by Geographic Region (2017-2022) & (K Units)
    Table 30. Global Neuroblastoma Treatment Drugs Sales Market Share Geographic Region (2017-2022)
    Table 31. Global Neuroblastoma Treatment Drugs Revenue by Geographic Region (2017-2022) & ($ millions)
    Table 32. Global Neuroblastoma Treatment Drugs Revenue Market Share by Geographic Region (2017-2022)
    Table 33. Global Neuroblastoma Treatment Drugs Sales by Country/Region (2017-2022) & (K Units)
    Table 34. Global Neuroblastoma Treatment Drugs Sales Market Share by Country/Region (2017-2022)
    Table 35. Global Neuroblastoma Treatment Drugs Revenue by Country/Region (2017-2022) & ($ millions)
    Table 36. Global Neuroblastoma Treatment Drugs Revenue Market Share by Country/Region (2017-2022)
    Table 37. Americas Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)
    Table 38. Americas Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2022)
    Table 39. Americas Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & ($ Millions)
    Table 40. Americas Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2022)
    Table 41. Americas Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
    Table 42. Americas Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)
    Table 43. Americas Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
    Table 44. Americas Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)
    Table 45. APAC Neuroblastoma Treatment Drugs Sales by Region (2017-2022) & (K Units)
    Table 46. APAC Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2022)
    Table 47. APAC Neuroblastoma Treatment Drugs Revenue by Region (2017-2022) & ($ Millions)
    Table 48. APAC Neuroblastoma Treatment Drugs Revenue Market Share by Region (2017-2022)
    Table 49. APAC Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
    Table 50. APAC Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)
    Table 51. APAC Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
    Table 52. APAC Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)
    Table 53. Europe Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)
    Table 54. Europe Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2022)
    Table 55. Europe Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & ($ Millions)
    Table 56. Europe Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2022)
    Table 57. Europe Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
    Table 58. Europe Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)
    Table 59. Europe Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
    Table 60. Europe Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)
    Table 61. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Country (2017-2022) & (K Units)
    Table 62. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Country (2017-2022)
    Table 63. Middle East & Africa Neuroblastoma Treatment Drugs Revenue by Country (2017-2022) & ($ Millions)
    Table 64. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Market Share by Country (2017-2022)
    Table 65. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Type (2017-2022) & (K Units)
    Table 66. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Type (2017-2022)
    Table 67. Middle East & Africa Neuroblastoma Treatment Drugs Sales by Application (2017-2022) & (K Units)
    Table 68. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)
    Table 69. Key Market Drivers & Growth Opportunities of Neuroblastoma Treatment Drugs
    Table 70. Key Market Challenges & Risks of Neuroblastoma Treatment Drugs
    Table 71. Key Industry Trends of Neuroblastoma Treatment Drugs
    Table 72. Neuroblastoma Treatment Drugs Raw Material
    Table 73. Key Suppliers of Raw Materials
    Table 74. Neuroblastoma Treatment Drugs Distributors List
    Table 75. Neuroblastoma Treatment Drugs Customer List
    Table 76. Global Neuroblastoma Treatment Drugs Sales Forecast by Region (2023-2028) & (K Units)
    Table 77. Global Neuroblastoma Treatment Drugs Sales Market Forecast by Region
    Table 78. Global Neuroblastoma Treatment Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
    Table 79. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Region (2023-2028)
    Table 80. Americas Neuroblastoma Treatment Drugs Sales Forecast by Country (2023-2028) & (K Units)
    Table 81. Americas Neuroblastoma Treatment Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 82. APAC Neuroblastoma Treatment Drugs Sales Forecast by Region (2023-2028) & (K Units)
    Table 83. APAC Neuroblastoma Treatment Drugs Revenue Forecast by Region (2023-2028) & ($ millions)
    Table 84. Europe Neuroblastoma Treatment Drugs Sales Forecast by Country (2023-2028) & (K Units)
    Table 85. Europe Neuroblastoma Treatment Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 86. Middle East & Africa Neuroblastoma Treatment Drugs Sales Forecast by Country (2023-2028) & (K Units)
    Table 87. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Forecast by Country (2023-2028) & ($ millions)
    Table 88. Global Neuroblastoma Treatment Drugs Sales Forecast by Type (2023-2028) & (K Units)
    Table 89. Global Neuroblastoma Treatment Drugs Sales Market Share Forecast by Type (2023-2028)
    Table 90. Global Neuroblastoma Treatment Drugs Revenue Forecast by Type (2023-2028) & ($ Millions)
    Table 91. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Type (2023-2028)
    Table 92. Global Neuroblastoma Treatment Drugs Sales Forecast by Application (2023-2028) & (K Units)
    Table 93. Global Neuroblastoma Treatment Drugs Sales Market Share Forecast by Application (2023-2028)
    Table 94. Global Neuroblastoma Treatment Drugs Revenue Forecast by Application (2023-2028) & ($ Millions)
    Table 95. Global Neuroblastoma Treatment Drugs Revenue Market Share Forecast by Application (2023-2028)
    Table 96. United Therapeutics Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 97. United Therapeutics Neuroblastoma Treatment Drugs Product Offered
    Table 98. United Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 99. United Therapeutics Main Business
    Table 100. United Therapeutics Latest Developments
    Table 101. Y-mAbs Therapeutics Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 102. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Product Offered
    Table 103. Y-mAbs Therapeutics Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 104. Y-mAbs Therapeutics Main Business
    Table 105. Y-mAbs Therapeutics Latest Developments
    Table 106. EUSA Pharma Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 107. EUSA Pharma Neuroblastoma Treatment Drugs Product Offered
    Table 108. EUSA Pharma Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 109. EUSA Pharma Main Business
    Table 110. EUSA Pharma Latest Developments
    Table 111. ANI Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 112. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
    Table 113. ANI Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 114. ANI Pharmaceuticals Main Business
    Table 115. ANI Pharmaceuticals Latest Developments
    Table 116. Baxter Healthcare Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 117. Baxter Healthcare Neuroblastoma Treatment Drugs Product Offered
    Table 118. Baxter Healthcare Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 119. Baxter Healthcare Main Business
    Table 120. Baxter Healthcare Latest Developments
    Table 121. Ingenus Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 122. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
    Table 123. Ingenus Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 124. Ingenus Pharmaceuticals Main Business
    Table 125. Ingenus Pharmaceuticals Latest Developments
    Table 126. Pfizer Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 127. Pfizer Neuroblastoma Treatment Drugs Product Offered
    Table 128. Pfizer Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 129. Pfizer Main Business
    Table 130. Pfizer Latest Developments
    Table 131. Hikma Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 132. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
    Table 133. Hikma Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 134. Hikma Pharmaceuticals Main Business
    Table 135. Hikma Pharmaceuticals Latest Developments
    Table 136. Teva Pharmaceuticals Basic Information, Neuroblastoma Treatment Drugs Manufacturing Base, Sales Area and Its Competitors
    Table 137. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Product Offered
    Table 138. Teva Pharmaceuticals Neuroblastoma Treatment Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2020-2022)
    Table 139. Teva Pharmaceuticals Main Business
    Table 140. Teva Pharmaceuticals Latest Developments
List of Figures
    Figure 1. Picture of Neuroblastoma Treatment Drugs
    Figure 2. Neuroblastoma Treatment Drugs Report Years Considered
    Figure 3. Research Objectives
    Figure 4. Research Methodology
    Figure 5. Research Process and Data Source
    Figure 6. Global Neuroblastoma Treatment Drugs Sales Growth Rate 2017-2028 (K Units)
    Figure 7. Global Neuroblastoma Treatment Drugs Revenue Growth Rate 2017-2028 ($ Millions)
    Figure 8. Neuroblastoma Treatment Drugs Sales by Region (2021 & 2028) & ($ millions)
    Figure 9. Product Picture of Cyclophosphamide
    Figure 10. Product Picture of Dinutuximab
    Figure 11. Product Picture of Naxitamab
    Figure 12. Product Picture of Doxorubicin Hydrochloride
    Figure 13. Product Picture of Vincristine Sulfate
    Figure 14. Product Picture of Other
    Figure 15. Global Neuroblastoma Treatment Drugs Sales Market Share by Type in 2021
    Figure 16. Global Neuroblastoma Treatment Drugs Revenue Market Share by Type (2017-2022)
    Figure 17. Neuroblastoma Treatment Drugs Consumed in Hospital
    Figure 18. Global Neuroblastoma Treatment Drugs Market: Hospital (2017-2022) & (K Units)
    Figure 19. Neuroblastoma Treatment Drugs Consumed in Clinic
    Figure 20. Global Neuroblastoma Treatment Drugs Market: Clinic (2017-2022) & (K Units)
    Figure 21. Neuroblastoma Treatment Drugs Consumed in Other
    Figure 22. Global Neuroblastoma Treatment Drugs Market: Other (2017-2022) & (K Units)
    Figure 23. Global Neuroblastoma Treatment Drugs Sales Market Share by Application (2017-2022)
    Figure 24. Global Neuroblastoma Treatment Drugs Revenue Market Share by Application in 2021
    Figure 25. Neuroblastoma Treatment Drugs Revenue Market by Company in 2021 ($ Million)
    Figure 26. Global Neuroblastoma Treatment Drugs Revenue Market Share by Company in 2021
    Figure 27. Global Neuroblastoma Treatment Drugs Sales Market Share by Geographic Region (2017-2022)
    Figure 28. Global Neuroblastoma Treatment Drugs Revenue Market Share by Geographic Region in 2021
    Figure 29. Global Neuroblastoma Treatment Drugs Sales Market Share by Region (2017-2022)
    Figure 30. Global Neuroblastoma Treatment Drugs Revenue Market Share by Country/Region in 2021
    Figure 31. Americas Neuroblastoma Treatment Drugs Sales 2017-2022 (K Units)
    Figure 32. Americas Neuroblastoma Treatment Drugs Revenue 2017-2022 ($ Millions)
    Figure 33. APAC Neuroblastoma Treatment Drugs Sales 2017-2022 (K Units)
    Figure 34. APAC Neuroblastoma Treatment Drugs Revenue 2017-2022 ($ Millions)
    Figure 35. Europe Neuroblastoma Treatment Drugs Sales 2017-2022 (K Units)
    Figure 36. Europe Neuroblastoma Treatment Drugs Revenue 2017-2022 ($ Millions)
    Figure 37. Middle East & Africa Neuroblastoma Treatment Drugs Sales 2017-2022 (K Units)
    Figure 38. Middle East & Africa Neuroblastoma Treatment Drugs Revenue 2017-2022 ($ Millions)
    Figure 39. Americas Neuroblastoma Treatment Drugs Sales Market Share by Country in 2021
    Figure 40. Americas Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2021
    Figure 41. United States Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 42. Canada Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 43. Mexico Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 44. Brazil Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 45. APAC Neuroblastoma Treatment Drugs Sales Market Share by Region in 2021
    Figure 46. APAC Neuroblastoma Treatment Drugs Revenue Market Share by Regions in 2021
    Figure 47. China Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 48. Japan Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 49. South Korea Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 50. Southeast Asia Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 51. India Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 52. Australia Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 53. Europe Neuroblastoma Treatment Drugs Sales Market Share by Country in 2021
    Figure 54. Europe Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2021
    Figure 55. Germany Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 56. France Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 57. UK Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 58. Italy Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 59. Russia Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 60. Middle East & Africa Neuroblastoma Treatment Drugs Sales Market Share by Country in 2021
    Figure 61. Middle East & Africa Neuroblastoma Treatment Drugs Revenue Market Share by Country in 2021
    Figure 62. Egypt Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 63. South Africa Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 64. Israel Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 65. Turkey Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 66. GCC Country Neuroblastoma Treatment Drugs Revenue Growth 2017-2022 ($ Millions)
    Figure 67. Manufacturing Cost Structure Analysis of Neuroblastoma Treatment Drugs in 2021
    Figure 68. Manufacturing Process Analysis of Neuroblastoma Treatment Drugs
    Figure 69. Industry Chain Structure of Neuroblastoma Treatment Drugs
    Figure 70. Channels of Distribution
    Figure 71. Distributors Profiles
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Please ask for Sample Report to see list of companies covered. Request Sample Report
Frequently Asked Questions
Global Neuroblastoma Treatment Drugs Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Global Neuroblastoma Treatment Drugs Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Global Neuroblastoma Treatment Drugs Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports